Joseph V Briggman

Title: **Joseph V Briggman: Innovator in Carcinoma Detection**

Introduction

Joseph V Briggman, an accomplished inventor based in Westford, MA, has made significant contributions to the field of biomedical research. With a total of three patents to his name, his work focuses on proteins that play a crucial role in the detection and treatment of carcinoma, particularly involving carcinoembryonic antigen (CEA).

Latest Patents

Briggman's latest innovations include two noteworthy patents related to CEA-binding proteins:

1. **CEA-binding protein and uses thereof**: This patent discloses a protein that specifically binds to carcinoembryonic antigen in the presence of divalent cation in vitro. The protein has a molecular weight of approximately 20 kD, as determined by SDS-polyacrylamide gel electrophoresis. It is glycosylated and includes the amino acid sequence detailed in the Sequence Listing as SEQ ID NO:4. The patent also covers antibodies that recognize the CEA binding protein, methods for detecting carcinoma, treatment methodologies, and a kit designed for patient screening.

2. **Binding protein for CEA and uses thereof**: Another patent by Briggman describes a similar protein that binds to carcinoembryonic antigen with a molecular weight of around 21 kD, also characterized by SDS-polyacrylamide gel electrophoresis. This glycosylated protein is described in the Sequence Listing as SEQ ID NO:2. Similar to the first patent, it includes antibodies, detection methods, treatment approaches, and a screening kit for carcinoma patients.

Career Highlights

Briggman has worked with notable organizations, including Applied Bio Technology and New England Deaconess Hospital Corporation. His experience in these institutions has fostered a deep understanding of the intersection between biotechnology and clinical applications.

Collaborations

Throughout his career, Joseph V Briggman has collaborated with talented individuals such as Sibusisiwe M Maswoswe and Carol A Toth. These partnerships have likely enhanced the impact and reach of his inventions in the medical field.

Conclusion

Joseph V Briggman stands out as an influential inventor in the realm of carcinoma research. His innovative patents demonstrate a commitment to advancing medical science and improving patient outcomes through the development of CEA-binding proteins. As the field of biomedical technology continues to evolve, Briggman's contributions will undoubtedly play a significant role in future advancements.